

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other independent professional adviser.

If you have sold or transferred all your shares, you should at once hand this circular, together with the accompanying form of proxy, to the purchaser(s) or transferee(s) or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s).

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

**REPURCHASE MANDATE AND GENERAL MANDATE,
PROPOSED RE-ELECTION OF RETIRING DIRECTORS,
PROPOSED NAME CHANGE
AND
NOTICE OF ANNUAL GENERAL MEETING**

A letter from the Board is set out on pages 5 to 11 of this circular.

A notice convening the annual general meeting of C-MER EYE CARE HOLDINGS LIMITED (the “Company”) to be held at Unit 1203B, 12/F, World-Wide House, 19 Des Voeux Road Central, Central, Hong Kong on Tuesday, 28 May 2024, at 3:00 p.m. is set forth on pages 24 to 28 of this circular.

Whether or not you are able to attend the said meeting, you are requested to complete the accompanying form of proxy in accordance with the instructions printed thereon and return it to the Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong in accordance with the instructions printed thereon as soon as possible and in any event not less than 48 hours before the time appointed for holding the annual general meeting (i.e. not later than Sunday, 26 May 2024 at 3:00 p.m.) or any adjournment thereof. **Completion and return of the accompanying form of proxy will not preclude you from subsequently attending and voting in person at the annual general meeting of the Company or any adjourned meeting should you so wish and in such event, the form of proxy previously submitted shall be deemed to be revoked.**

23 April 2024

TABLE OF CONTENTS

	<i>Page</i>
DEFINITIONS	1
EXPECTED TIMETABLE	4
LETTER FROM THE BOARD	
Introduction	5
Repurchase Mandate	6
General Mandate	6
Re-election of retiring Directors	7
Proposed Name Change	8
Annual General Meeting	9
Proxy arrangement	9
Closure of register of members	10
Voting by way of a poll	10
Recommendation	10
Responsibility statement	10
APPENDIX I — EXPLANATORY STATEMENT FOR THE REPURCHASE MANDATE	12
APPENDIX II — INFORMATION OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING AND OTHER INFORMATION ...	16
NOTICE OF THE ANNUAL GENERAL MEETING	24

DEFINITIONS

In this circular, unless the context otherwise requires, the following terms and expressions shall have the following meanings:

“acting in concert”	has the meaning ascribed thereto in the Takeovers Codes;
“Annual General Meeting”	the annual general meeting of the Company to be held at Unit 1203B, 12/F, World-Wide House, 19 Des Voeux Road Central, Central, Hong Kong on Tuesday, 28 May 2024, at 3:00 p.m. or any adjournment thereof (as the case may be);
“Articles” or “Articles of Association”	the articles of association of the Company;
“associates”	has the meaning ascribed to it under the Listing Rules;
“Board”	the board of Directors;
“close associate(s)”	has the meaning ascribed to it under the Listing Rules;
“Companies Act”	the Companies Act (As Revised) of the Cayman Islands;
“Company”	C-MER EYE CARE HOLDINGS LIMITED (希瑪眼科醫療控股有限公司), an exempted company incorporated in the Cayman Islands with limited liability on 1 February 2016, and the Shares of which are listed on the Stock Exchange (stock code: 3309);
“Controlling Shareholders”	has the meaning ascribed to it under the Listing Rules and, in the context of our Company for the purpose of this circular, C-MER Group Limited, Dr. LAM Shun Chiu Dennis and Ms. LI Xiaoting;
“core connected person(s)”	has the meaning ascribed to it under the Listing Rules;
“Director(s)”	the director(s) of the Company;
“General Mandate”	the general mandate proposed to be granted to the Directors to exercise all the powers of the Company to allot, issue and otherwise deal with new Shares or to grant any offers, agreements or options which would or might require Shares to be issued, allotted or disposed of not exceeding 20% of the total number of the Shares in issue as of the date of passing the resolution approving the said mandate;

DEFINITIONS

“Group”	the Company and its subsidiaries;
“Hong Kong”	Hong Kong Special Administrative Region of the People’s Republic of China;
“Latest Practicable Date”	15 April 2024, being the latest practicable date prior to the printing of this circular for ascertaining certain information for inclusion in this circular;
“Listing Rules”	The Rules Governing the Listing of Securities on the Stock Exchange;
“Notice”	the notice dated 23 April 2024 convening the Annual General Meeting as set forth on pages 24 to 28 of this circular;
“Ordinary Resolutions”	the proposed ordinary resolutions in respect of the matters referred to in the Notice;
“PRC”	People’s Republic of China;
“Proposed Name Change”	the proposed change of the English name of the Company from “C-MER EYE CARE HOLDINGS LIMITED” to “C-MER Medical Holdings Limited”, and the dual foreign name in Chinese of the Company from “希瑪眼科醫療控股有限公司” to “希瑪醫療控股有限公司”;
“Register of Members”	the register of members of the Company maintained by the Registrar in Hong Kong;
“Registrar”	the branch share registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17/F., Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong;
“Repurchase Mandate”	the general mandate proposed to be granted to the Directors to exercise the powers of the Company to purchase Shares up to a maximum of 10% of the total number of the Shares in issue as of the date of passing of the resolution approving the said mandate;
“SFO”	Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong);

DEFINITIONS

“Share(s)”	ordinary share(s) of HK\$0.10 each in the issued share capital of the Company;
“Shareholder(s)”	the registered holder(s) of the Share(s);
“Stock Exchange”	The Stock Exchange of Hong Kong Limited;
“Takeovers Codes”	The Codes on Takeovers and Mergers and Share Buy-backs;
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong;
“%”	per cent.

EXPECTED TIMETABLE

Dispatch of this circular and notice of the Annual General Meeting Tuesday, 23 April 2024

Latest time for lodging transfer forms of Shares to qualify for entitlements to attend and vote at the Annual General Meeting 4:30 p.m. on Wednesday, 22 May 2024

Closure of Register of Members for the purpose of determining the voting rights for the Annual General Meeting(both dates inclusive) from Thursday, 23 May 2024 to Tuesday, 28 May 2024


Latest time for lodging forms of proxy for the Annual General Meeting (in any event not less than 48 hours before the time appointed for holding the Annual General Meeting or any adjournment thereof) 3:00 p.m. on Sunday, 26 May 2024

Date and time of the Annual General Meeting 3:00 p.m. on Tuesday, 28 May 2024

Notes:

1. All dates and time set out in this circular refer to Hong Kong dates and time.
2. Dates or deadlines specified in this circular are indicative only and may be varied by the Company. Any consequential changes to the expected timetable will be published or notified to the Shareholders as and when appropriate and in accordance with the Listing Rules.

LETTER FROM THE BOARD



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

Executive Directors:

Dr. LAM Shun Chiu Dennis (*Chairman*)

Ms. LI Xiaoting

Dr. LEE Yau Wing Vincent

Independent non-executive Directors:

Dr. Rex AU YEUNG Pak-kuen (*Vice Chairman*)

Mr. MA Andrew Chiu Cheung

Mr. IP Shu Kwan Stephen

Mr. YIN Ke

Registered office:

Cricket Square

Hutchins Drive

P.O. Box 2681

Grand Cayman KY1-1111

Cayman Islands

Head office and principal place

of business in Hong Kong:

Suite 1535, Central Building

1-3 Pedder Street

Hong Kong

23 April 2024

To the Shareholders:

Dear Sir or Madam,

**REPURCHASE MANDATE AND GENERAL MANDATE,
PROPOSED RE-ELECTION OF RETIRING DIRECTORS,
PROPOSED NAME CHANGE
AND
NOTICE OF ANNUAL GENERAL MEETING**

INTRODUCTION

The purpose of this circular is to give you information on the following resolutions proposed to be tabled at the Annual General Meeting, so as to enable you to make an informed decision on the resolutions at the Annual General Meeting.

LETTER FROM THE BOARD

The resolutions include (i) the grant of the Repurchase Mandate, (ii) the grant of the General Mandate, (iii) the extension of the General Mandate by the aggregate number of shares repurchased under the Repurchase Mandate, (iv) the re-election of retiring Directors, and (v) the Proposed Name Change.

REPURCHASE MANDATE

On 30 May 2023, an ordinary resolution was passed by the Shareholders to give a general mandate to the Directors to exercise the powers of the Company to repurchase its own Shares. Such general mandate will lapse at the conclusion of the Annual General Meeting.

At the Annual General Meeting, an ordinary resolution will be proposed to grant to the Directors a general and unconditional mandate to exercise all powers of the Company to repurchase Shares subject to the criteria set forth in this circular. In particular, you should note that the maximum number of Shares that may be repurchased pursuant to the Repurchase Mandate will be such number which represents 10% of the total number of the Shares in issue as of the date of passing of the resolution, subject to the requirements of the Listing Rules. The Repurchase Mandate will end on the earliest of the date of the next annual general meeting of the Company, the date by which the next annual general meeting of the Company is required to be held by any applicable laws or the Articles and the date upon which such authority is revoked or varied by ordinary resolution of the Shareholders in general meeting.

In accordance with the Listing Rules, the Company is required to send to the Shareholders an explanatory statement, which is set forth in Appendix I to this circular.

GENERAL MANDATE

On 30 May 2023, an ordinary resolution was passed by the Shareholders to give a general mandate to the Directors to allot, issue and deal with Shares. Such general mandate will lapse at the conclusion of the Annual General Meeting.

At the Annual General Meeting, an ordinary resolution will be proposed to grant to the Directors a general and unconditional mandate to allot, issue and deal with further Shares or to grant any offers, agreements or options which would or might require Shares to be issued, allotted or disposed of, representing up to 20% of the total number of the Shares in issue as of the date of passing of the resolution. As of the Latest Practicable Date, the total number of the Shares in issue was 1,255,560,870 and they were all fully paid up or credited as fully paid-up. Assuming that there is no change in the total number of Shares in issue between the period from the Latest Practicable Date to the date of passing the aforesaid resolution, the maximum number of Shares which may be issued pursuant to the aforesaid general and unconditional mandate on the date of passing the aforesaid resolution will be 251,112,174 Shares.

LETTER FROM THE BOARD

Subject to the passing of the aforesaid ordinary resolutions of the Repurchase Mandate and the General Mandate, a separate ordinary resolution will also be proposed for the Shareholders to consider and, if thought fit, approve the extension of the General Mandate by adding to the aggregate number of Shares which may be allotted or agreed conditionally or unconditionally to be allotted by the Directors pursuant to the General Mandate the number of Shares purchased under the Repurchase Mandate, if granted.

RE-ELECTION OF RETIRING DIRECTORS

According to Article 84 of the Articles, Dr. LEE Yau Wing Vincent, Dr. Rex AU YEUNG Pak-kuen, Mr. MA Andrew Chiu Cheung and Mr. IP Shu Kwan Stephen shall retire from office by rotation at the Annual General Meeting. According to Article 83 of the Articles, Mr. YIN Ke was appointed as independent non-executive Director by the Directors with effect from 3 July 2023 and shall hold office only until the Annual General Meeting. All of them, being eligible, will offer themselves for re-election at the Annual General Meeting.

In proposing Dr. AU YEUNG, Mr. MA, Mr. IP and Mr. YIN to be re-elected as independent non-executive Directors at the Annual General Meeting, the nomination committee of the Company (the “**Nomination Committee**”) reviewed the structure and composition of the Board and the confirmation of independence provided by each of Dr. AU YEUNG, Mr. MA, Mr. IP and Mr. YIN pursuant to Rule 3.13 of the Listing Rules. The nominations were made in accordance with the nomination policy of the Company and the objective criteria (including without limitation, gender, age, cultural and educational background, professional experience, skills, knowledge and length of service), with due regard for the benefits of diversity, as set out under the board diversity policy of the Company. The Nomination Committee had also taken into account the working profile, extensive experience, contributions of each of such independent non-executive Directors and their commitment to their role and it was satisfied with their independence having regard to the independence criteria as set out in Rule 3.13 of the Listing Rules. The Nomination Committee considers that Dr. AU YEUNG, Mr. MA, Mr. IP and Mr. YIN will continue to bring valuable business experience, knowledge from different industries and professionalism to the Board for its efficient and effective functioning and diversity. The Board accepted the Nomination Committee’s nomination and recommended Dr. AU YEUNG, Mr. MA, Mr. IP and Mr. YIN to stand for re-election as independent non-executive Directors by the Shareholders at the Annual General Meeting.

Particulars of the retiring Directors who are proposed to be re-elected at the Annual General Meeting and further information in relation to the re-election of Directors are set forth in Appendix II to this circular. Re-election of retiring Directors will be individually voted on by the Shareholders.

LETTER FROM THE BOARD

PROPOSED NAME CHANGE

Reference is made to the Company's announcement dated 26 March 2024.

The Board proposes to change the English name of the Company from "C-MER EYE CARE HOLDINGS LIMITED" to "C-MER Medical Holdings Limited", and the dual foreign name in Chinese of the Company from "希瑪眼科醫療控股有限公司" to "希瑪醫療控股有限公司".

Conditions for the Proposed Name Change

The Proposed Name Change is subject to the following conditions:

- (i) the passing of a special resolution by the Shareholders at the Annual General Meeting approving the Proposed Name Change; and
- (ii) the Registrar of Companies in the Cayman Islands approving the Proposed Name Change by issuing a certificate of incorporation on change of name.

Subject to the satisfaction of the conditions set out above, the Proposed Name Change will take effect from the date of issue of a certificate of incorporation on change of name by the Registrar of Companies in the Cayman Islands. The Company will carry out the necessary registration and/or filing procedures with the Registrar of Companies in the Cayman Islands and the Companies Registry in Hong Kong.

To the best of the Director's knowledge, information and belief, having made all reasonable enquiries, none of the Shareholders is interested in the Proposed Name Change and would be required to abstain from voting at the AGM on the Proposed Name Change.

Reasons for the Proposed Name Change

The Company is an ophthalmic, dental and other medical service provider in Hong Kong and Mainland China. The Board considers that the Proposed Name Change will better reflect the identification of the current business mix, strategic business plan and future development direction of the Group. In addition, the Board believes that the new English name and the new dual foreign name in Chinese of the Company will better promote the Group's corporate image for its future business development. Therefore, the Board is of the view that the Proposed Name Change is in the best interests of the Company and the Shareholders as a whole.

LETTER FROM THE BOARD

Effects of the Proposed Name Change

The Proposed Name Change will not affect any rights of the Shareholders or the daily business operations and financial position of the Group. Upon the Proposed Name Change becoming effective, all existing share certificates in issue bearing the current name of the Company will, after the Proposed Name Change becoming effective, continue to be evidence of title to the ordinary shares of the Company and will continue to be valid for trading, settlement, registration and delivery purposes. Therefore, there will not be any arrangement for free exchange of the issued share certificates of the Company for new share certificates bearing the new name of the Company. Any issue of new share certificates after the Proposed Name Change becoming effective will be under the new name of the Company. In addition, subject to the confirmation by the Stock Exchange, the English and Chinese stock short names of the Company for trading in the securities on the Stock Exchange will also be changed after the Proposed Name Change becoming effective. Subject to the Proposed Name Change becoming effective, the Company may also adopt a new company logo.

Further announcement(s) will be made by the Company to inform the Shareholders of the effective date of the Proposed Name Change and the new English and Chinese stock short names of the Company for trading in the securities on the Stock Exchange and other relevant information as and when appropriate.

ANNUAL GENERAL MEETING

A notice of the Annual General Meeting is set forth on pages 24 to 28 of this circular. At the Annual General Meeting, resolutions will be proposed to approve, among other things, the grant of the Repurchase Mandate, the grant of the General Mandate, the extension of the General Mandate by the aggregate number of shares repurchased under the Repurchase Mandate, the re-election of retiring Directors and the Proposed Name Change. The Annual General Meeting will be held at Unit 1203B, 12/F, World-Wide House, 19 Des Voeux Road Central, Central, Hong Kong, on Tuesday, 28 May 2024, at 3:00 p.m.

PROXY ARRANGEMENT

A form of proxy for the Annual General Meeting is enclosed with this circular. To be valid, the form of proxy must be completed in accordance with the instructions printed thereon and deposited, together with the power of attorney or other authority (if any) under which it is signed or a certified copy of such power of attorney or authority, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, as soon as possible and in any event not later than 48 hours before the time appointed for holding the Annual General Meeting (i.e. not later than Sunday, 26 May 2024 at 3:00 p.m.) or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the Annual General Meeting or any adjournment thereof (as the case may be) should you so wish and in such event, the form of proxy previously submitted shall be deemed to be revoked.

LETTER FROM THE BOARD

CLOSURE OF REGISTER OF MEMBERS

The Register of Members will be closed from Thursday, 23 May 2024 to Tuesday, 28 May 2024 (both days inclusive), during which period no transfer of Shares will be effected in order to determine the entitlement to attend and vote at the Annual General Meeting. All share transfers accompanied by the relevant share certificates, must be lodged with the Registrar at Shops 1712–1716, 17/F., Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Wednesday, 22 May 2024 for such purpose.

VOTING BY WAY OF A POLL

According to Rule 13.39(4) of the Listing Rules and the Articles, any vote of shareholders at a general meeting must be taken by poll except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. Therefore, poll voting for all proposed resolutions of the Company will be adopted with at the Annual General Meeting.

The poll results will be published on the websites of the Stock Exchange and the Company after conclusion of the Annual General Meeting.

RECOMMENDATION

The Board is of the opinion that the grant of the Repurchase Mandate and the General Mandate, the extension of the General Mandate by the aggregate number of shares repurchased under the Repurchase Mandate, the proposed re-election of retiring Directors and the Proposed Name Change are in the best interests of the Company and the Shareholders as a whole and accordingly recommend all the Shareholders to vote in favour of the relevant resolutions to be proposed at the Annual General Meeting.

RESPONSIBILITY STATEMENT

This circular includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors collectively and individually accept full responsibility for the accuracy of the information contained in this circular and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief:

- (a) the information contained in this circular is accurate and complete in all material respects and not misleading;

LETTER FROM THE BOARD

- (b) there are no other matters the omission of which would make any statement in this circular misleading; and
- (c) all opinion expressed in this circular have been arrived at after due and careful consideration and are found on bases and assumptions that are fair and reasonable.

By order of the Board
C-MER EYE CARE HOLDINGS LIMITED
Dr. LAM Shun Chiu Dennis
Chairman, Chief Executive Officer
and Executive Director

This appendix contains particulars that are required by the Listing Rules to be included in an explanatory statement to enable the Shareholders to make an informed decision on whether to vote for or against the resolutions to be proposed at the Annual General Meeting in relation to the Repurchase Mandate.

PROPOSED REPURCHASE MANDATE

It is proposed that the Directors be granted the Repurchase Mandate such that they may exercise the powers of the Company to repurchase up to 10% of the total number of the Shares in issue as of the date of passing of the relevant resolution. As of the Latest Practicable Date, the total number of the Shares in issue was 1,255,560,870 and they were all fully paid up or credited as fully paid-up. Accordingly, the exercise of the Repurchase Mandate in full (being the repurchase of 10% of the total number of the Shares in issue as of the date of the passing of the resolution to approve the Repurchase Mandate) would enable the Company to repurchase a maximum of 125,556,087 Shares (assuming no Share is issued or repurchased after the Latest Practicable Date and up to the date of passing of the relevant resolution).

REASONS FOR REPURCHASES

The Directors believe that the Repurchase Mandate is in the best interests of the Company and its Shareholders. Whilst it is not possible to anticipate in advance any specific circumstance in which the Directors might think it appropriate to repurchase Shares, the Directors believe that an ability to do so would give the Company additional flexibility that would be beneficial to the Company and the Shareholders as such repurchases may, depending on market conditions and funding arrangements at that time, lead to an enhancement of the net asset value for each Share and/or earnings for each Share. Shareholders can be assured that the Directors would only make such purchases in circumstances where they consider them to be in the best interests of the Company.

FUNDING OF REPURCHASES

In making repurchases, the Company proposes to apply funds legally available for such purpose in accordance with its memorandum of association, the Articles, the Listing Rules and the Companies Act. Under the Companies Act, Shares repurchased by the Company may only be paid out of profits or out of the proceeds of a fresh issue of Shares made for the purpose, or, if so authorised by its memorandum of association, the Articles and subject to the Companies Act, out of capital. Any premium payable on share repurchases may only be paid out of profits of the Company or out of the Company's share premium account, or, if so authorised by the Articles and subject to the Companies Act, out of capital. In accordance with the Companies Act, the Shares so repurchased would remain part of the authorised but unissued share capital of the Company.

IMPACT OF REPURCHASE

As compared with the financial position of the Company as of 31 December 2023 (being the date of its latest audited financial statements), the Directors consider that there may be a material adverse impact on the working capital or gearing position of the Company if the Repurchase Mandate is exercised in full during the proposed repurchase period. However, the Directors do not intend to exercise the Repurchase Mandate to such extent as it would, in the circumstances, have a material adverse effect on the working capital or the gearing level of the Company (as compared with the position disclosed in its most recent published audited financial statements) which in the opinion of the Directors are from time to time appropriate for the Company.

PRICE OF SHARES

During each of the previous twelve months up to the Latest Practicable Date, the highest and lowest prices at which the Shares have been traded on the Stock Exchange were as follows:

	Share Price	
	Highest <i>HK\$</i>	Lowest <i>HK\$</i>
2023		
April	4.80	4.18
May	4.50	3.72
June	4.19	3.74
July	4.20	3.76
August	4.14	3.40
September	3.83	3.46
October	3.98	3.60
November	3.98	3.55
December	3.60	3.30
2024		
January	3.45	2.60
February	3.11	2.39
March	3.25	2.77
April (up to the Latest Practicable Date)	2.93	2.64

UNDERTAKING

None of the Directors nor, to the best of their knowledge and belief having made all reasonable enquiries, any of their close associates has any present intention to sell any Shares to the Company in the event that the Repurchase Mandate is approved by the Shareholders.

As of the Latest Practicable Date, none of the core connected persons of the Company has notified the Company that he/she/it has a present intention to sell his/her/its Shares to the Company, nor has he/she/it undertaken not to do so, in the event that the Repurchase Mandate is approved by the Shareholders.

The Directors have undertaken to the Stock Exchange that they will exercise the power of the Company to make purchases pursuant to the Repurchase Mandate in accordance with the Listing Rules, the memorandum of association and the Articles, the Companies Act and all applicable laws of Cayman Islands.

TAKEOVERS CODES

If on the exercise of the power to repurchase Shares pursuant to the Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purposes of rule 32 of the Takeovers Codes. As a result, a Shareholder, or group of Shareholders acting in concert depending on the level of increase of the Shareholders' interest, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with rule 26 of the Takeovers Codes.

As of the Latest Practicable Date, the Controlling Shareholders together held an aggregate of 689,114,553 Shares, representing approximately 54.9% of the total number of the Shares in issue.

In the event that the Directors exercise in full the power to repurchase Shares which is proposed to be granted, then (if the present shareholdings otherwise remained the same) the equity interests in the Company held by the Controlling Shareholders would increase to approximately to 61.0% of the total number of Shares in issue.

The Directors are not aware of any consequence under the Takeovers Codes as a result of a repurchase of Shares made under the Repurchase Mandate and have no present intention to exercise the power to repurchase Shares pursuant to the Repurchase Mandate to such an extent as to result in takeover obligations.

The Directors have no intention to make share repurchase on the Stock Exchange to such extent as may result in the public shareholding becoming less than the prescribed minimum percentage under the Listing Rules.

SHARE REPURCHASES MADE BY THE COMPANY

The Company made the following repurchases of Shares on the Stock Exchange during the six months immediately preceding the Latest Practicable Date:

Date of Repurchase	No. of shares repurchased	Consideration per share		Total Consideration Paid HK\$
		<i>Highest</i>	<i>Lowest</i>	
		HK\$	HK\$	
16 October 2023	250,000	3.94	3.91	986,906
17 October 2023	230,000	3.90	3.87	898,192
18 October 2023	254,000	3.90	3.84	986,071
19 October 2023	254,000	3.84	3.78	971,476
20 October 2023	282,000	3.72	3.68	1,050,391
24 October 2023	176,000	3.69	3.68	650,697
25 October 2023	174,000	3.69	3.67	643,084
30 October 2023	306,000	3.82	3.77	1,167,444
31 October 2023	260,000	3.82	3.79	996,185
1 November 2023	260,000	3.88	3.79	1,005,200
2 November 2023	274,000	3.89	3.82	1,062,036
3 November 2023	216,000	3.91	3.90	848,144
6 November 2023	214,000	3.98	3.95	852,314
7 November 2023	218,000	3.90	3.83	844,737
9 November 2023	276,000	3.77	3.71	1,040,878
14 November 2023	214,000	3.70	3.68	792,221
15 November 2023	268,000	3.81	3.74	1,018,553
16 November 2023	326,000	3.80	3.74	1,234,305
Total	<u>4,452,000</u>			<u>17,048,834</u>

**RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL
GENERAL MEETING**

Set forth below is a summary of the biographical information on the retiring Directors proposed to be re-elected at the Annual General Meeting. Dr. LEE Yau Wing Vincent, Dr. Rex AUYEUNG Pak-ken, Mr. MA Andrew Chiu Cheung and Mr. IP Shu Kwan Stephen will retire by rotation in accordance with Article 84 of the Articles. Mr. YIN Ke was appointed as independent non-executive Director with effect from 3 July 2023 and shall hold office only until the Annual General Meeting in accordance with Article 83 of the Articles.

Executive Director

Dr. LEE Yau Wing Vincent (李佑榮醫生), aged 55, is our executive Director. Dr. LEE has been practicing for us since January 2012 and is our Head of Hong Kong Operation. Dr. LEE obtained a Bachelor of Medicine and Bachelor of Surgery from the Chinese University of Hong Kong in December 1993. Dr. LEE completed the Postgraduate Diploma in Epidemiology and Biostatistics in 2008 and was awarded a Master of Science degree in Epidemiology and Biostatistics in 2009 all from the Chinese University of Hong Kong. Dr. LEE has been a registered medical practitioner in Hong Kong since 1994.

Dr. LEE has been a Fellow of Royal College of Surgeons of Edinburgh since 1998, Fellow of College of Ophthalmologists of Hong Kong since 1998, a Fellow of College of Surgeons of Hong Kong since 1998 and a Fellow of the Hong Kong Academy of Medicine in the specialty of ophthalmology since 2002.

Dr. LEE was the President of the Hong Kong Ophthalmological Society (“**HKOS**”). Dr. LEE was the Chief Editor of the Newsletter of the HKOS called Eye Opener. Dr. LEE was elected as the regional secretary of Hong Kong and has represented Hong Kong in the Asia-Pacific Academy of Ophthalmology. Dr. LEE holds two ophthalmic patents as an inventor. He was awarded “Ten Outstanding Young Person of Hong Kong” in 2009.

Prior to joining us, Dr. LEE was the Honorary Clinical Assistant Professor (from 2003 to 2007) and later the Honorary Clinical Associate Professor since March 2011 in the Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong. Dr. LEE was the Assistant Professor, the Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong, the Visiting Professor, Shantou University Medical College and the Consultant, the Department of Ophthalmology and Visual Sciences, New Territories East Cluster, Hospital Authority.

Dr. LEE has no relationship with any Directors, senior management or substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Dr. LEE does not hold any other positions with the Company or other members of the Group.

Dr. LEE has not held any directorship in other listed public companies in the last three years.

As disclosed in the Company's announcement dated 2 September 2020, Dr. LEE was ordered to be reprimanded by the Inquiry Panel of the Medical Council of Hong Kong for his failure to prevent the use of a title, which was not a quotable qualification approved by the Medical Council of Hong Kong and/or was misleading to the public, but which was contained in an advertisement or article published by a local newspaper on 24 September 2018.

Independent non-executive Directors

Dr. Rex AUYEUNG Pak-kuen GBS JP, (歐陽伯權博士), aged 71, is our independent non-executive Director since November 2020 and vice chairman since November 2021. Dr. AUYEUNG is a chairperson of the nomination committee of the Company and had been a member of the audit committee of the Company from 30 May 2023 to 3 July 2023. He is currently the chairman and non-executive director of MTR Corporation Limited (stock code: 0066), an independent non-executive director of China Construction Bank (Asia) Corporation Limited and an advisor to Nippon Life Asia Pacific (Regional HQ) Pte. Ltd (a company incorporated in Singapore). Dr. AUYEUNG has over 40 years of experience in the insurance industry in Canada and Hong Kong. Dr. AUYEUNG was Chairman – Asia of the Principal Financial Group Inc. (“PFG”), a Fortune 500 company, responsible for PFG's overall businesses in Asia. During his time with PFG, Dr. AUYEUNG represented PFG and its member companies across Asia in building and expanding PFG's relationship with clients, joint venture partners and strategic investors, and assisting in business development across all products lines of PFG. Dr. AUYEUNG also actively serves the public sector and is currently a member of the Board of Directors of the Investor and Financial Education Council under the Securities and Futures Commission, a board member of Bo Charity Foundation (Food Angel) and a convenor of the Advisory Committee of the Jockey Club Community eHealth Care Project. Dr. AUYEUNG was previously the chairman of Hong Kong Strategy for Financial Literacy Sub-committee on Stakeholder Coordination and Collaboration, an observer of the Independent Police Complaints Council Observers Scheme and a member of the Independent Review Committee on Hong Kong's Franchised Bus Service. Dr. AUYEUNG holds a Bachelor of Environmental Studies (Urban and Regional Planning) Honours Degree from the University of Waterloo, Canada. He was awarded an Honorary Fellowship by the City University of Hong Kong in 2013 and conferred a Doctor of Business Administration, honoris causa, by Lingnan University in 2020.

Dr. AUYEUNG meets the independence guidelines set out in Rule 3.13 of the Listing Rules and the Company has received his independence confirmation. The Board considers him to be independent.

Dr. AUYEUNG has no relationship with any Directors, senior management or substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Dr. AUYEUNG does not hold any other positions with the Company or other members of the Group.

Save as disclosed above, Dr. AUYEUNG has not held any directorship in other listed public companies in the last three years.

Mr. MA Andrew Chiu Cheung (馬照祥先生), aged 82, is our independent non-executive Director since December 2017. Mr. MA is the chairperson of the audit committee and a member of the remuneration committee and the nomination committee of the Company.

Mr. MA holds a Bachelor's degree in Economics from The London School of Economics and Political Science (The University of London). Mr. MA is the Fellow Member of each of the Institute of Chartered Accountants in England & Wales, the Hong Kong Institute of Certified Public Accountants, The Taxation Institute of Hong Kong, The Hong Kong Institute of Directors and a full member of The Hong Kong Management Association.

Mr. MA has over 40 years of experience in accounting, auditing and finance. Mr. MA is a founder and served as a director of Mayee Management Limited until his retirement on 1 January 2024. He is the founder and former director of AMA CPA Limited (formerly known as Andrew Ma DFK (CPA) Ltd) in Hong Kong.

Mr. MA is also an independent non-executive director of Asiaray Media Group Limited (Stock code: 01993), and S.A.I. Leisure Group Company Limited (Stock code: 1832) all of which are listed on the main board of the Stock Exchange. Mr. MA previously served as an independent non-executive director of C.P. Pokphand Co. Ltd. (Stock code: 00043), Chong Hing Bank Limited (Stock code: 01111) and China Resources Power Holdings Company Limited (Stock code: 00836), the shares of all of which are listed on the Main Board of the Stock Exchange, until his retirement on 5 June 2020, 14 May 2021 and 15 September 2021, respectively.

Mr. MA meets the independence guidelines set out in Rule 3.13 of the Listing Rules and the Company has received his independence confirmation. The Board considers him to be independent.

Mr. MA has no relationship with any Directors, senior management or substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Mr. MA does not hold any other positions with the Company or other members of the Group.

Save as disclosed above, Mr. MA has not held any directorship in other listed public companies in the last three years.

Mr. IP Shu Kwan Stephen GBS JP, (葉澍堃先生) aged 72, is our independent non-executive Director since November 2020. Mr. IP is the chairperson of the remuneration committee of the Company and a member of the audit committee of the Company. Mr. IP graduated from the University of Hong Kong with a degree in social sciences in 1973 and completed the Program for Management Development of the Harvard Business School in 1986. Mr. IP joined the Hong Kong Government in November 1973 and was promoted to the rank of Director of Bureau in April 1997. He worked in the Hong Kong Government as a Principal Official from July 1997 to June 2007. Senior positions held by Mr. IP in the past include Commissioner of Insurance, Commissioner for Labour, Secretary for Economic Services and Secretary for Financial Services. Mr. IP took up the position of Secretary for Economic Development and Labour in July 2002. His portfolio in respect of economic development covered air and sea transport, logistics development, tourism, energy, postal services, meteorological services, competition and consumer protection. He was also responsible for labour policies including matters relating to employment services, labour relations and employees rights.

In his capacity as Secretary for Economic Development and Labour, Mr. IP was a member of the Hong Kong Airport Authority Board, the Mandatory Provident Fund Authority Board, the Hong Kong International Theme Parks Company Board as well as the Chairman of the Logistics Development Council, Port Development Board, Maritime Industry Council and Aviation Development Advisory Committee. Mr. IP retired from the Hong Kong Government in July 2007. Mr. IP received the Gold Bauhinia Star award from the Hong Kong Government in 2001, and is an unofficial Justice of the Peace since 2007. Mr. IP has been appointed as an independent non-executive director of six other listed companies on the main board of the Stock Exchange, namely, China Resources Building Materials Technology Holdings Limited (formerly known as China Resources Cement Holdings Limited) (stock code: 1313) since August 2008, Lai Sun Development Company Limited (stock code: 0488) since December 2009, Kingboard Laminates Holdings Limited (stock code: 1888) since May 2011, Luk Fook Holdings (International) Limited (stock code: 0590) since October 2011, Nameson Holdings Limited (stock code: 1982) since April 2018 and Million Cities Holdings Limited (stock code: 2892) since June 2018.

Mr. IP meets the independence guidelines set out in Rule 3.13 of the Listing Rules and the Company has received his independence confirmation. The Board considers him to be independent.

Mr. IP has no relationship with any Directors, senior management or substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Mr. IP does not hold any other positions with the Company or other members of the Group.

Save as disclosed above, Mr. IP has not held any directorship in other listed public companies in the last three years.

Mr. YIN Ke (殷可), aged 60, is our independent non-executive Director since July 2023. Mr. YIN is the member of the audit committee and nomination committee of the Company.

Mr. YIN graduated with a bachelor's degree in electrical engineering and a master's degree in economics from Zhejiang University, the PRC.

Mr. YIN previously worked as a Secretary to the President of the Shenzhen Stock Exchange. He also served as the Deputy General Manager and an Executive Director of Jun'an Securities Co., Ltd., a Board Director of Guotai Junan Securities Co., Ltd., the President and an Executive Director of China United Securities Co., Ltd., a Director and the Deputy Chief Executive Officer of CITIC Capital Holdings Limited, a Non-executive Director of CITIC Dameng Holdings Limited, an Independent Director of CCB Principal Asset Management Co., Ltd., the Chief Executive Officer of CITIC Securities International Limited and an Executive Director and the Vice Chairman of CITIC Pacific Limited. In addition, Mr. YIN served as the Vice Chairman of CITIC Securities Company Limited (Stock Code: 6030) from 2011 to 2016 and its Executive Director from 2009 to 2017, and a Non-executive Director of CITIC Limited (formerly known as CITIC Pacific Limited) (Stock Code: 267) from 2009 to 2014, both of which are listed on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). He was also a Non-executive Director of Dah Chong Hong Holdings Limited from 2010 to 2012 and from 2018 to 2020, which was delisted from the Stock Exchange in 2020. He was a non-executive director of Hui Xian Asset Management Limited from October 2011 to January 2018. Mr. YIN was a member of the Financial Service Committee of Hong Kong Trade Development Council from 2017 to 2022.

Mr. YIN currently serves as an External Director of Shandong Heavy Industry Group Co., Ltd. and an Independent Non-executive Director of Hui Xian Real Estate Investment Trust (stock code: 87001), which is listed on the Stock Exchange, an Independent Non-executive Director of Focus Media Information Technology Co., Ltd. (Stock Code: 002027.SZ), which is listed on the Shenzhen Stock Exchange. Mr. YIN also serves as a Senior Advisor to CPP Investments. He is a director of 北京東方廣場有限公司 (Beijing Oriental Plaza Co., Ltd.). Mr. YIN was appointed as the independent non-executive director of Morgan Stanley Securities (China) Limited with effect from 26 February 2024.

Mr. YIN meets the independence guidelines set out in Rule 3.13 of the Listing Rules and the Company has received his independence confirmation. The Board considers him to be independent.

Mr. YIN has no relationship with any Directors, senior management or substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Mr. YIN does not hold any other positions with the Company or other members of the Group.

Save as disclosed above, Mr. YIN has not held any directorship in other listed public companies in the last three years.

FURTHER INFORMATION ON THE RETIRING DIRECTORS

Disclosure of interests

As of the Latest Practicable Date, the interests and short positions of the retiring Directors in the shares, underlying shares and debentures of the Company which would have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions), or would be required, pursuant to section 352 of the SFO, to be entered in the register required to be kept therein, or would be required pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers set forth in the Listing Rules to be notified to the Company and the Stock Exchange, were as follows:

Long and short positions in the Shares and underlying Shares of the Company

Name of Director	Nature of interests	Interest in issued Shares/ underlying Shares	Approximate percentage of the Company's issued Shares
Dr. LEE Yau Wing Vincent	Beneficial owner	13,203,000 (L) (Note 1)	1.1%
Dr. Rex AU YEUNG Pak-kuen	Interest of spouse	300,000 (L) (Notes 1 and 2)	0.02%
	Beneficial owner	200,000 (L) (Notes 1 and 3)	0.02%

Notes:

1. The letter “L” represents the individual’s long positions in Shares.
2. Representing interest held by spouse.
3. Dr. Rex AUYEUNG Pak-kuen held 200,000 share options under the post-IPO share option scheme approved and adopted by the Company pursuant to the resolutions of the Shareholders passed on 28 June 2017.

Save as disclosed above, so far as the Directors are aware as of the Latest Practicable Date, the retiring Directors did not have any other interests in Shares or underlying Shares within the meaning of Part XV of the SFO.

Particulars of service agreement and/or letters of appointment of Directors

Dr. LEE Yau Wing Vincent entered into a service agreement with the Company. Particulars of the agreement are summarized below:

- (i) service agreement is of a term of three years commencing on 13 December 2023 and shall continue thereafter until terminated in accordance with the terms of the agreement. Under the agreement, either party may terminate the agreement at any time by giving to the other not less than 3 months’ prior written notice; and
- (ii) Dr. LEE is entitled to an annual director’s fee of HK\$240,000.

Dr. Rex AUYEUNG Pak-kuen entered into a letter of appointment with the Company. Particulars of the letter of appointment are summarised below:

- (i) Appointment is of a term of three years commencing on 6 November 2023 and shall continue thereafter until terminated in accordance with the terms of the agreement. He is subject to retirement by rotation and re-election at the Annual General Meeting in accordance with the Articles.
- (ii) Dr. AUYEUNG is entitled to receive an annual director’s fee of HK\$600,000.

Mr. MA Andrew Chiu Cheung entered into a letter of appointment with the Company. Particulars of the letter of appointment are summarised below:

- (i) Appointment is of a term of three years commencing on 13 December 2023 and shall continue thereafter until terminated in accordance with the terms of the agreement. He is subject to retirement by rotation and re-election at the Annual General Meeting in accordance with the Articles.
- (ii) Mr. MA is entitled to receive an annual director’s fee of HK\$240,000.

Mr. IP Shu Kwan Stephen entered into a letter of appointment with the Company. Particulars of the letter of appointment are summarised below:

- (i) Appointment is of a term of three years commencing on 6 November 2023 and shall continue thereafter until terminated in accordance with the terms of the agreement. He is subject to retirement by rotation and re-election at the Annual General Meeting in accordance with the Articles.
- (ii) Mr. IP is entitled to receive an annual director's fee of HK\$240,000.

Mr. YIN Ke entered into a letter of appointment with the Company. Particulars of the letter of appointment are summarised below:

- (i) Appointment is of a term of three years commencing on 3 July 2023 and shall continue thereafter until terminated in accordance with the terms of the agreement. He is subject to re-election at the Annual General Meeting in accordance with the Articles.
- (ii) Mr. YIN is entitled to receive an annual director's fee of HK\$240,000.

Policy on Directors' emoluments


Emoluments of the executive Directors are determined with reference to (i) the basis of the relevant executive Director's experience, responsibility, workload and the time devoted to the Group; (ii) non-cash benefits that may be provided to the executive Directors under their remuneration package; and (iii) at the discretion of the Board, options and/or awards that may be granted to the executive Directors pursuant to the post-IPO share option scheme and/or the share award scheme, as part of their remuneration.

Emoluments of the independent non-executive Directors are determined with reference to (i) the duties and responsibilities of the independent non-executive Directors; and (ii) their mutual agreement with the Company.

Other information

Save as disclosed above, there are no other matters concerning the retiring Directors that need to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

NOTICE OF THE ANNUAL GENERAL MEETING



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED 希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

NOTICE OF THE ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that an annual general meeting (the “**Annual General Meeting**”) of C-MER EYE CARE HOLDINGS LIMITED (the “**Company**”) will be held at Unit 1203B, 12/F, World-Wide House, 19 Des Voeux Road Central, Central, Hong Kong, on Tuesday, 28 May 2024, at 3:00 p.m. for the following purposes:

ORDINARY BUSINESS

1. To receive and consider the audited consolidated financial statements and the reports of the directors (the “**Director(s)**”) and the auditor (the “**Auditor**”) of the Company, PricewaterhouseCoopers, for the financial year ended 31 December 2023;
2. (A) (i) to re-elect Dr. LEE Yau Wing Vincent as an executive Director;

(ii) to re-elect Dr. Rex AU YEUNG Pak-kuen as an independent non-executive Director;

(iii) to re-elect Mr. MA Andrew Chiu Cheung as an independent non-executive Director;

(iv) to re-elect Mr. IP Shu Kwan Stephen as an independent non-executive Director;

(v) to re-elect Mr. YIN Ke as an independent non-executive Director;

(B) to authorise the board of Directors (the “**Board**”) to determine the remuneration of the Directors;
3. to re-appoint the Auditor and to authorise the Board to fix its remuneration;

NOTICE OF THE ANNUAL GENERAL MEETING

SPECIAL BUSINESS

4. to consider and, if thought fit, pass with or without amendments the following resolutions as ordinary resolutions of the Company:

4A. **“THAT:**

- (a) subject to paragraph (c) below, the exercise by the Directors during the Relevant Period (as defined in paragraph (d) below) of all the powers of the Company to repurchase issued ordinary shares of the Company of HK\$0.10 each (the **“Shares”**) on The Stock Exchange of Hong Kong Limited (the **“Stock Exchange”**) or on any other stock exchange on which the Shares may be listed and recognised by the Securities and Futures Commission and the Stock Exchange for this purpose, subject to and in accordance with all applicable laws, the memorandum and articles of association of the Company (the **“Articles”**) and requirements of the Rules Governing the Listing of Securities on the Stock Exchange (the **“Listing Rules”**), as amended from time to time, be and is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) shall be in addition to any other authorisations given to the Directors and shall authorise the Directors on behalf of the Company during the Relevant Period to procure the Company to repurchase its Shares at a price determined by the Directors;
- (c) the number of Shares to be repurchased by the Directors pursuant to the approval in paragraph (a) above shall not exceed 10% of the total number of the Shares in issue as of the date of passing of this resolution, and the said approval shall be limited accordingly; and
- (d) for the purpose of this resolution:

“Relevant Period” means the period from the date of passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company; or
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by any applicable laws or the Articles to be held; or
- (iii) the date upon which the authority set forth in this resolution is revoked or varied by way of an ordinary resolution of the shareholders of the Company in general meeting.”

NOTICE OF THE ANNUAL GENERAL MEETING

4B. “THAT:

- (a) subject to paragraph (c) below, the exercise by the Directors during the Relevant Period (as defined in paragraph (d) below) of all the powers of the Company to allot, issue and otherwise deal with additional Shares or securities convertible into Shares and to make or grant offers, agreements, options and rights of exchange or conversion which might require the exercise of such powers, subject to and in accordance with all applicable laws, the Articles and the Listing Rules, be and is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) above, shall be in addition to any other authorisations given to the Directors and shall authorise the Directors during the Relevant Period to make or grant offers, agreements, options (including bonds, warrants, debentures and other securities convertible into Shares) and rights of exchange or conversion which would or might require the exercise of such powers after the end of the Relevant Period;
- (c) the aggregate number of the Shares allotted, issued or otherwise dealt with or agreed conditionally or unconditionally to be allotted, issued or otherwise dealt with (whether pursuant to an option or otherwise) by the Directors pursuant to the approval granted in paragraph (a) above, otherwise than pursuant to (i) a rights issue (as defined in paragraph (d) below), or (ii) the exercise of any options granted under the share option schemes or similar arrangement for the time being adopted or to be adopted for the grant or issue to officers and/or employees of the Company and/or its subsidiaries, of options to subscribe for, or rights to acquire Shares of the Company approved by the Stock Exchange, or (iii) any scrip dividend or similar arrangement providing for the allotment of Shares in lieu of the whole or part of a dividend on Shares of the Company in accordance with the Articles, shall not exceed 20% of the total number of the Shares in issue as of the date of passing of this resolution, and the said approval shall be limited accordingly; and
- (d) for the purpose of this resolution:

“Relevant Period” shall have the same meaning as ascribed to it under the resolution set forth in resolution No. 4A(d) above; and

“Rights issue” means the allotment, issue or grant of Shares open for a period fixed by the Directors to holders of the Shares or any class of Shares thereof on the register of members on a fixed record date in proportion to their then holdings of such Shares or of such class thereof (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any

NOTICE OF THE ANNUAL GENERAL MEETING

restrictions or obligations under the laws of any relevant jurisdiction, or the requirements of any recognised regulatory body or any stock exchange in, any territory applicable to the Company).”

4C. **“THAT:**

conditional upon the passing of resolutions Nos. 4A and 4B, the general mandate granted to the Directors pursuant to resolution No. 4B be and is hereby extended by the addition thereto an amount representing the aggregate number of Shares repurchased by the Company under the authority granted pursuant to the resolution No. 4A, **PROVIDED THAT** such amount shall not exceed 10% of the total number of the Shares in issue as of the date of passing of this resolution.”

SPECIAL RESOLUTION

5. **“THAT, AS A SPECIAL RESOLUTION:**

Subject to and conditional upon the approval of the Registrar of Companies of the Cayman Islands (the **“Registrar”**) having been obtained by way of issue of a certificate of incorporation on change of name, the existing English name of the Company be changed from **“C-MER EYE CARE HOLDINGS LIMITED”** to **“C-MER Medical Holdings Limited”**, and the existing dual foreign name in Chinese of the Company be changed from **“希瑪眼科醫療控股有限公司”** to **“希瑪醫療控股有限公司”** (the **“Proposed Name Change”**) with effect from the date of the certificate of incorporation on change of name issued by the Registrar of Companies in the Cayman Islands, and that anyone of the Directors, the secretary or the registered office provider or the share registrars of the Company be and is/are hereby authorized to do all such acts and things and execute all such documents, including under seal where appropriate, as he/she/ they may consider necessary, desirable or expedient for the purpose of or in connection with, the implementation of and giving effect to the Proposed Name Change and to attend to any necessary registration and/or filings for and on behalf of the Company.”

By order of the Board
C-MER EYE CARE HOLDINGS LIMITED
CHAN Wa Ping
Company Secretary

Hong Kong, 23 April 2024

NOTICE OF THE ANNUAL GENERAL MEETING

Notes:

1. Any member entitled to attend and vote at the Annual General Meeting is entitled to appoint another person as his or her or its proxy to attend and vote instead of him or her or it. A member may appoint a proxy in respect of only part of his or her or its holding of Shares. A proxy need not be a shareholder of the Company.
2. The instrument appointing a proxy shall be in writing under the hand of the appointor or of his or her attorney duly authorised in writing or, if the appointor is a corporation, either under its seal or under the hand of an officer or attorney duly authorised to sign the same. In the case of an instrument of proxy purporting to be signed on behalf of a corporation by an officer thereof it shall be assumed, unless the contrary appears, that such officer was duly authorised to sign such instrument of proxy on behalf of the corporation without further evidence of the facts.
3. The instrument appointing a proxy and the power of attorney or other authority, if any, under which it is signed, or a certified copy of such power of attorney or authority, must be deposited at the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for holding the Annual General Meeting (i.e. not later than Sunday, 26 May 2024 at 3:00 p.m.) or any adjournment thereof.
4. Delivery of an instrument appointing a proxy shall not preclude a shareholder of the Company from attending and voting in person at the Annual General Meeting and in such event, the instrument appointing a proxy previously submitted shall be deemed to be revoked.
5. Where there are joint holders of any Share any one of such joint holders may vote, either in person or by proxy, in respect of such Share as if he were solely entitled thereto, but if more than one of such joint holders be present at the Annual General Meeting the vote of the most senior person who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and for this purpose seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.
6. The register of members of the Company will be closed from Thursday, 23 May 2024 to Tuesday, 28 May 2024 (both days inclusive), during which period no transfer of Shares will be effected in order to determine the entitlement to attend and vote at the Annual General Meeting. All share transfers accompanied by the relevant share certificates, must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17/F., Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Wednesday, 22 May 2024 for such purpose.
7. As of the date of this notice, Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting, Dr. LEE Yau Wing Vincent are the executive Directors; and Dr. Rex AU YEUNG Pak-kuen, Mr. MA Andrew Chiu Cheung, Mr. IP Shu Kwan Stephen and Mr. YIN Ke are the independent non-executive Directors.